{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:22:30Z","timestamp":1787664150518,"version":"build-2736575974"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>Neuroinflammation is increasingly recognised as a key feature of Alzheimer\u2019s Disease (AD) pathophysiology. Markers of glial reactivity, sTREM2 and YKL-40, are elevated in mild cognitive impairment (MCI) and AD, but their associations with core pathology across these stages have not yet been systematically investigated. This systematic review and meta-analysis examined their cross-sectional and longitudinal associations with core pathological biomarkers of AD, and examine how these relationships may evolve dynamically across the disease continuum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search conducted across Medline, Embase, PsycINFO, PubMed and Scopus (PROSPERO: CRD420250653864) identified 42 studies for sTREM2 and 44 for YKL-40 that were included in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Meta-analyses revealed that both markers showed robust positive associations with pTau181, tTau and NfL (pooled\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.31\u20130.55), including in covariate-adjusted correlations. In contrast, associations with A\u03b2 pathology (CSF A\u03b242\/40, A\u03b2-PET) were weaker and not significant in covariate-adjusted estimates. Meta-regression analyses revealed that glial-tau associations were strongest in cognitively unimpaired (CU) individuals, and progressively weakened in MCI and AD, independent of age effects. Longitudinal data were limited and summarised descriptively; glial reactivity predicts increases in soluble CSF hyperphosphorylated tau pathology, yet is concurrently associated with slower accumulation of insoluble PET-detectable amyloid and tau aggregates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicate that sTREM2 and YKL-40 preferentially associate with tauopathy and neurodegeneration over pathological A\u03b2 accumulation. The progressive attenuation of glial-pathology coupling may reflect glial saturation or \u201cexhaustion\u201d with disease progression, offering new insights into how impaired glial responses may be involved in AD pathophysiology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41380-026-03787-x","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:33:26Z","timestamp":1785429206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroinflammatory markers sTREM2 and YKL-40 in association with Alzheimer\u2019s disease pathology: a systematic review and meta-analysis"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6265-6015","authenticated-orcid":false,"given":"Rachael","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5993-2246","authenticated-orcid":false,"given":"Anastasia","family":"Suraev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-5929","authenticated-orcid":false,"given":"Shawn","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9076-3068","authenticated-orcid":false,"given":"Robert","family":"Zachariae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Piccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4996-1630","authenticated-orcid":false,"given":"Michael T.","family":"Heneka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9076-2778","authenticated-orcid":false,"given":"Sharon L.","family":"Naismith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5683-8222","authenticated-orcid":false,"given":"Johannes C.","family":"Michaelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"3787_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A, Norton N, Fast T, Fr\u00f6lich L, Georges J, Holzapfel D, et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimer\u2019s Dement. 2023;19:658\u201370. https:\/\/doi.org\/10.1002\/alz.12694","journal-title":"Alzheimer\u2019s Dement"},{"key":"3787_CR2","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7:e105\u2013e25. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8","journal-title":"Lancet Public Health"},{"key":"3787_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson 3rd","year":"2023","unstructured":"Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, et al. Hallmarks of neurodegenerative diseases. Cell. 2023;186:693\u2013714. https:\/\/doi.org\/10.1016\/j.cell.2022.12.032","journal-title":"Cell"},{"key":"3787_CR4","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"JrCR Jack","year":"2024","unstructured":"Jack JrCR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimer\u2019s Dement"},{"key":"3787_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1083\/jcb.201709069","volume":"217","author":"DV Hansen","year":"2018","unstructured":"Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer\u2019s disease. J Cell Biol. 2018;217:459\u201372. https:\/\/doi.org\/10.1083\/jcb.201709069","journal-title":"J Cell Biol"},{"key":"3787_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16:358\u201372. https:\/\/doi.org\/10.1038\/nrn3880","journal-title":"Nat Rev Neurosci"},{"key":"3787_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae396","volume":"6","author":"F Leipp","year":"2024","unstructured":"Leipp F, Vialaret J, Mohaupt P, Coppens S, Jaffuel A, Niehoff AC, et al. Glial fibrillary acidic protein in Alzheimer\u2019s disease: a narrative review. Brain Commun. 2024;6:fcae396. https:\/\/doi.org\/10.1093\/braincomms\/fcae396","journal-title":"Brain Commun"},{"key":"3787_CR8","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1038\/s41380-025-02939-9","volume":"30","author":"MT Heneka","year":"2025","unstructured":"Heneka MT, Gauthier S, Chandekar SA, Hviid Hahn-Pedersen J, Bentsen MA, Zetterberg H. Neuroinflammatory fluid biomarkers in patients with Alzheimer\u2019s disease: a systematic literature review. Mol Psychiatry. 2025;30:2783\u201398. https:\/\/doi.org\/10.1038\/s41380-025-02939-9","journal-title":"Mol Psychiatry"},{"key":"3787_CR9","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144:3505\u201316. https:\/\/doi.org\/10.1093\/brain\/awab223","journal-title":"Brain"},{"key":"3787_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12291","volume":"14","author":"D Shir","year":"2022","unstructured":"Shir D, Graff-Radford J, Hofrenning EI, Lesnick TG, Przybelski SA, Lowe VJ, et al. Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer\u2019s disease and vascular pathology. Alzheimers Dement (Amst). 2022;14:e12291. https:\/\/doi.org\/10.1002\/dad2.12291","journal-title":"Alzheimers Dement (Amst)"},{"key":"3787_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1148-y","volume":"15","author":"JT Li","year":"2018","unstructured":"Li JT, Zhang Y. TREM2 regulates innate immunity in Alzheimer\u2019s disease. J Neuroinflammation. 2018;15:107. https:\/\/doi.org\/10.1186\/s12974-018-1148-y","journal-title":"J Neuroinflammation"},{"key":"3787_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-015-0040-9","volume":"10","author":"MM Painter","year":"2015","unstructured":"Painter MM, Atagi Y, Liu C-C, Rademakers R, Xu H, Fryer JD, et al. TREM2 in CNS homeostasis and neurodegenerative disease. Mol Neurodegener. 2015;10:43. https:\/\/doi.org\/10.1186\/s13024-015-0040-9","journal-title":"Mol Neurodegener"},{"key":"3787_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1420731","volume":"16","author":"C Lin","year":"2024","unstructured":"Lin C, Kong Y, Chen Q, Zeng J, Pan X, Miao J. Decoding sTREM2: its impact on Alzheimer\u2019s disease - a comprehensive review of mechanisms and implications. Front Aging Neurosci. 2024;16:1420731. https:\/\/doi.org\/10.3389\/fnagi.2024.1420731","journal-title":"Front Aging Neurosci"},{"key":"3787_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100631","volume":"296","author":"A Vilalta","year":"2021","unstructured":"Vilalta A, Zhou Y, Sevalle J, Griffin JK, Satoh K, Allendorf DH, et al. Wild-type sTREM2 blocks A\u03b2 aggregation and neurotoxicity, but the Alzheimer\u2019s R47H mutant increases A\u03b2 aggregation. J Biol Chem. 2021;296:100631. https:\/\/doi.org\/10.1016\/j.jbc.2021.100631","journal-title":"J Biol Chem"},{"key":"3787_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09118-9","volume":"10","author":"L Zhong","year":"2019","unstructured":"Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer\u2019s disease model. Nat Commun. 2019;10:1365. https:\/\/doi.org\/10.1038\/s41467-019-09118-9","journal-title":"Nat Commun"},{"key":"3787_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med. 2013;368:107\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1211103","journal-title":"N Engl J Med"},{"key":"3787_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell. 2015;160:1061\u201371. https:\/\/doi.org\/10.1016\/j.cell.2015.01.049","journal-title":"Cell"},{"key":"3787_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1084\/jem.20171529","volume":"215","author":"WM Song","year":"2018","unstructured":"Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med. 2018;215:745\u201360. https:\/\/doi.org\/10.1084\/jem.20171529","journal-title":"J Exp Med"},{"key":"3787_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-018-0262-8","volume":"13","author":"PJ Cheng-Hathaway","year":"2018","unstructured":"Cheng-Hathaway PJ, Reed-Geaghan EG, Jay TR, Casali BT, Bemiller SM, Puntambekar SS, et al. The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer\u2019s disease. Mol Neurodegener. 2018;13:29. https:\/\/doi.org\/10.1186\/s13024-018-0262-8","journal-title":"Mol Neurodegener"},{"key":"3787_CR20","first-page":"5","volume":"51","author":"MH Kazakova","year":"2009","unstructured":"Kazakova MH, Sarafian VS. YKL-40\u2013a novel biomarker in clinical practice? Folia Med (Plovdiv). 2009;51:5\u201314.","journal-title":"Folia Med (Plovdiv)"},{"key":"3787_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1750-3639.2011.00550.x","volume":"22","author":"D Bonneh-Barkay","year":"2012","unstructured":"Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012;22:530\u201346. https:\/\/doi.org\/10.1111\/j.1750-3639.2011.00550.x","journal-title":"Brain Pathol"},{"key":"3787_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-7-34","volume":"7","author":"D Bonneh-Barkay","year":"2010","unstructured":"Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation. 2010;7:34. https:\/\/doi.org\/10.1186\/1742-2094-7-34","journal-title":"J Neuroinflammation"},{"key":"3787_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-025-00801-8","volume":"20","author":"PF Mwale","year":"2025","unstructured":"Mwale PF, Hsieh C-T, Yen T-L, Jan J-S, Taliyan R, Yang C-H, et al. Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications. Mol Neurodegener. 2025;20:7. https:\/\/doi.org\/10.1186\/s13024-025-00801-8","journal-title":"Mol Neurodegener"},{"key":"3787_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/14789450.2017.1304217","volume":"14","author":"F Baldacci","year":"2017","unstructured":"Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer\u2019s disease and other neurodegenerative diseases. Expert Rev Proteomics. 2017;14:285\u201399. https:\/\/doi.org\/10.1080\/14789450.2017.1304217","journal-title":"Expert Rev Proteomics"},{"key":"3787_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","volume":"25","author":"MT Heneka","year":"2025","unstructured":"Heneka MT, van der Flier WM, Jessen F, Hoozemanns J, Thal DR, Boche D, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2025;25:321\u201352. https:\/\/doi.org\/10.1038\/s41577-024-01104-7","journal-title":"Nat Rev Immunol"},{"key":"3787_CR26","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fnagi.2024.1407980","volume":"16","author":"R Wang","year":"2024","unstructured":"Wang R, Zhan Y, Zhu W, Yang Q, Pei J. Association of soluble TREM2 with Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and meta-analysis. Front Aging Neurosci. 2024;16:2024. https:\/\/doi.org\/10.3389\/fnagi.2024.1407980","journal-title":"Front Aging Neurosci"},{"key":"3787_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2024.100819","volume":"40","author":"R Childs","year":"2024","unstructured":"Childs R, Karamacoska D, Lim CK, Steiner-Lim GZ. \u201cLet\u2019s talk about sex, inflammaging, and cognition, baby\u201d: A meta-analysis and meta-regression of 106 case-control studies on mild cognitive impairment and Alzheimer\u2019s disease. Brain Behav Immun Health. 2024;40:100819. https:\/\/doi.org\/10.1016\/j.bbih.2024.100819","journal-title":"Brain Behav Immun Health"},{"key":"3787_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2025.112960","volume":"212","author":"R Ebrahimi","year":"2025","unstructured":"Ebrahimi R, Salehi Amniyeh Khozani AA, Masouri MM, Seifi M, Hashempoor A, Mohammad Soltani S, et al. Neurodegeneration and glial activation related blood biomarkers in Alzheimer\u2019s disease: A systematic review and an updated meta- analysis. Exp Gerontol. 2025;212:112960. https:\/\/doi.org\/10.1016\/j.exger.2025.112960","journal-title":"Exp Gerontol"},{"key":"3787_CR29","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3389\/fneur.2026.1768353","volume":"17","author":"Q Yang","year":"2026","unstructured":"Yang Q, Wang R, Pei J, Fu Q, Zhan Y, Zhu W. Association of Alzheimer\u2019s disease progression with YKL40 levels in peripheral blood and cerebrospinal fluid: a systematic review and meta-analysis. Front Neurol. 2026;17:2026. https:\/\/doi.org\/10.3389\/fneur.2026.1768353","journal-title":"Front Neurol"},{"key":"3787_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s41232-023-00277-3","volume":"43","author":"A Sobue","year":"2023","unstructured":"Sobue A, Komine O, Yamanaka K. Neuroinflammation in Alzheimer\u2019s disease: microglial signature and their relevance to disease. Inflamm Regen. 2023;43:26. https:\/\/doi.org\/10.1186\/s41232-023-00277-3","journal-title":"Inflamm Regen"},{"key":"3787_CR31","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3787_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/01621459.1961.10482120","volume":"56","author":"RL Gustafson","year":"1961","unstructured":"Gustafson RL. Partial Correlations in Regression Computations. J Am Stat Assoc. 1961;56:363\u20137. https:\/\/doi.org\/10.1080\/01621459.1961.10482120","journal-title":"J Am Stat Assoc"},{"key":"3787_CR33","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"Doing Meta-Analysis With R: A Hands-On Guide","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing Meta-Analysis With R: A Hands-On Guide. 1st ed. Boca Raton, FL and London: Chapman & Hall\/CRC Press; 2021.","edition":"1st ed."},{"key":"3787_CR34","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. https:\/\/doi.org\/10.1136\/bmj.d4002","journal-title":"BMJ"},{"key":"3787_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/xeb.0000000000000055","volume":"13","author":"E Aromataris","year":"2015","unstructured":"Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015;13:132\u201340. https:\/\/doi.org\/10.1097\/xeb.0000000000000055","journal-title":"Int J Evid Based Healthc"},{"key":"3787_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-019-0562-4","volume":"12","author":"S Abu-Rumeileh","year":"2019","unstructured":"Abu-Rumeileh S, Steinacker P, Polischi B, Mammana A, Bartoletti-Stella A, Oeckl P, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimer\u2019s Res Ther. 2019;12:2. https:\/\/doi.org\/10.1186\/s13195-019-0562-4","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"3787_CR37","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/wnl.0000000000001859","volume":"85","author":"D Alcolea","year":"2015","unstructured":"Alcolea D, Mart\u00ednez-Lage P, S\u00e1nchez-Juan P, Olazar\u00e1n J, Ant\u00fanez C, Izagirre A, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology. 2015;85:626\u201333. https:\/\/doi.org\/10.1212\/wnl.0000000000001859","journal-title":"Neurology"},{"key":"3787_CR38","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.neurobiolaging.2015.03.001","volume":"36","author":"D Alcolea","year":"2015","unstructured":"Alcolea D, Vilaplana E, Pegueroles J, Montal V, S\u00e1nchez-Juan P, Gonz\u00e1lez-Su\u00e1rez A, et al. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer\u2019s disease. Neurobiol Aging. 2015;36:2018\u201323. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.03.001","journal-title":"Neurobiol Aging"},{"key":"3787_CR39","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3233\/jad-140624","volume":"42","author":"A Antonell","year":"2014","unstructured":"Antonell A, Mansilla A, Rami L, Llad\u00f3 A, Iranzo A, Olives J, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer\u2019s disease. J Alzheimers Dis. 2014;42:901\u20138. https:\/\/doi.org\/10.3233\/jad-140624","journal-title":"J Alzheimers Dis"},{"key":"3787_CR40","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jalz.2017.01.021","volume":"13","author":"F Baldacci","year":"2017","unstructured":"Baldacci F, Toschi N, Lista S, Zetterberg H, Blennow K, Kilimann I, et al. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer\u2019s disease. Alzheimers Dement. 2017;13:993\u20131003. https:\/\/doi.org\/10.1016\/j.jalz.2017.01.021","journal-title":"Alzheimers Dement"},{"key":"3787_CR41","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216987","volume":"15","author":"D Biel","year":"2023","unstructured":"Biel D, Su\u00e1rez\u2010Calvet M, Hager P, Rubinski A, Dewenter A, Steward A, et al. sTREM2 is associated with amyloid\u2010related p\u2010tau increases and glucose hypermetabolism in Alzheimer\u2019s disease. EMBO Mol Med. 2023;15:e16987. https:\/\/doi.org\/10.15252\/emmm.202216987","journal-title":"EMBO Mol Med"},{"key":"3787_CR42","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jalz.2019.01.004","volume":"15","author":"I Bos","year":"2019","unstructured":"Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer\u2019s disease spectrum. Alzheimers Dement. 2019;15:644\u201354. https:\/\/doi.org\/10.1016\/j.jalz.2019.01.004","journal-title":"Alzheimers Dement"},{"key":"3787_CR43","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.neuron.2021.12.016","volume":"110","author":"F Brosseron","year":"2022","unstructured":"Brosseron F, Maass A, Kleineidam L, Ravichandran KA, Gonz\u00e1lez PG, McManus RM, et al. Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer\u2019s disease. Neuron. 2022;110:1009\u201322.e4. https:\/\/doi.org\/10.1016\/j.neuron.2021.12.016","journal-title":"Neuron"},{"key":"3787_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-022-01118-0","volume":"15","author":"F Brosseron","year":"2023","unstructured":"Brosseron F, Maass A, Kleineidam L, Ravichandran KA, Kolbe C-C, Wolfsgruber S, et al. Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer\u2019s disease: results from the DELCODE study. Alzheimer\u2019s ResTher. 2023;15:13. https:\/\/doi.org\/10.1186\/s13195-022-01118-0","journal-title":"Alzheimer\u2019s ResTher"},{"key":"3787_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-018-0353-3","volume":"10","author":"F Brosseron","year":"2018","unstructured":"Brosseron F, Trasch\u00fctz A, Widmann CN, Kummer MP, Tacik P, Santarelli F, et al. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2018;10:25. https:\/\/doi.org\/10.1186\/s13195-018-0353-3","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"3787_CR46","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry. 2010;68:903\u201312. https:\/\/doi.org\/10.1016\/j.biopsych.2010.08.025","journal-title":"Biol Psychiatry"},{"key":"3787_CR47","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1002\/alz.13399","volume":"19","author":"JL Dage","year":"2023","unstructured":"Dage JL, Eloyan A, Thangarajah M, Hammers DB, Fagan AM, Gray JD, et al. Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer\u2019s Disease Study. Alzheimer\u2019s Dement. 2023;19:S115\u2013S25. https:\/\/doi.org\/10.1002\/alz.13399","journal-title":"Alzheimer\u2019s Dement"},{"key":"3787_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-03072-x","volume":"14","author":"M Daniilidou","year":"2024","unstructured":"Daniilidou M, Holleman J, Hagman G, K\u00e5reholt I, Asp\u00f6 M, Brinkmalm A, et al. Neuroinflammation, cerebrovascular dysfunction and diurnal cortisol biomarkers in a memory clinic cohort: Findings from the Co-STAR study. Transl Psychiatry. 2024;14:364. https:\/\/doi.org\/10.1038\/s41398-024-03072-x","journal-title":"Transl Psychiatry"},{"key":"3787_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0742-9","volume":"16","author":"Y Deming","year":"2016","unstructured":"Deming Y, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez MV, et al. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. BMC Neurol. 2016;16:217. https:\/\/doi.org\/10.1186\/s12883-016-0742-9","journal-title":"BMC Neurol"},{"key":"3787_CR50","doi-asserted-by":"publisher","first-page":"7543","DOI":"10.3390\/ijms25147543","volume":"25","author":"J Doroszkiewicz","year":"2024","unstructured":"Doroszkiewicz J, Kulczy\u0144ska-Przybik A, Dulewicz M, Mroczko J, Borawska R, S\u0142owik A, et al. Associations between Microglia and Astrocytic Proteins and Tau Biomarkers across the Continuum of Alzheimer\u2019s Disease. Int J Mol Sci. 2024;25:7543.","journal-title":"Int J Mol Sci"},{"key":"3787_CR51","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012308","volume":"12","author":"M Ewers","year":"2020","unstructured":"Ewers M, Biechele G, Su\u00e1rez\u2010Calvet M, Sacher C, Blume T, Morenas\u2010Rodriguez E, et al. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta\u2010amyloid accumulation. EMBO Mol Med. 2020;12:e12308. https:\/\/doi.org\/10.15252\/emmm.202012308","journal-title":"EMBO Mol Med"},{"key":"3787_CR52","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3233\/jad-200293","volume":"76","author":"C Falcon","year":"2020","unstructured":"Falcon C, Grau-Rivera O, Su\u00e1rez-Calvet M, Bosch B, S\u00e1nchez-Valle R, Arenaza-Urquijo EM, et al. Sex differences of longitudinal brain changes in cognitively unimpaired adults. J Alzheimers Dis. 2020;76:1413\u201322. https:\/\/doi.org\/10.3233\/jad-200293","journal-title":"J Alzheimers Dis"},{"key":"3787_CR53","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1038\/s41380-022-01716-2","volume":"27","author":"JP Ferrari-Souza","year":"2022","unstructured":"Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang Y-T, Leffa DT, et al. Astrocyte biomarker signatures of amyloid-\u03b2 and tau pathologies in Alzheimer\u2019s disease. Mol Psychiatry. 2022;27:4781\u20139. https:\/\/doi.org\/10.1038\/s41380-022-01716-2","journal-title":"Mol Psychiatry"},{"key":"3787_CR54","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3389\/fmolb.2020.627931","volume":"7","author":"E Ferri","year":"2021","unstructured":"Ferri E, Rossi PD, Geraci A, Ciccone S, Cesari M, Arosio B. The sTREM2 Concentrations in the Blood: A Marker of Neurodegeneration? Front Mol Biosci. 2021;7:2020. https:\/\/doi.org\/10.3389\/fmolb.2020.627931","journal-title":"Front Mol Biosci"},{"key":"3787_CR55","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/cercor\/bhz240","volume":"30","author":"NB Halaas","year":"2020","unstructured":"Halaas NB, Henjum K, Blennow K, Dakhil S, Idland AV, Nilsson LN, et al. CSF sTREM2 and Tau work together in predicting increased temporal lobe atrophy in older adults. Cereb Cortex. 2020;30:2295\u2013306. https:\/\/doi.org\/10.1093\/cercor\/bhz240","journal-title":"Cereb Cortex"},{"key":"3787_CR56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-015-0161-y","volume":"7","author":"K Hellwig","year":"2015","unstructured":"Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2015;7:74. https:\/\/doi.org\/10.1186\/s13195-015-0161-y","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"3787_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13195-016-0182-1","volume":"8","author":"K Henjum","year":"2016","unstructured":"Henjum K, Almdahl IS, \u00c5rskog V, Minthon L, Hansson O, Fladby T, et al. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2016;8:17. https:\/\/doi.org\/10.1186\/s13195-016-0182-1","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"3787_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-016-0071-x","volume":"11","author":"A Heslegrave","year":"2016","unstructured":"Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer\u2019s disease. Mol Neurodegener. 2016;11:3. https:\/\/doi.org\/10.1186\/s13024-016-0071-x","journal-title":"Mol Neurodegener"},{"key":"3787_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02796-9","volume":"20","author":"YS Hok-A-Hin","year":"2023","unstructured":"Hok-A-Hin YS, del Campo M, Boiten WA, Stoops E, Vanhooren M, Lemstra AW, et al. Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer\u2019s disease. J Neuroinflammation. 2023;20:107. https:\/\/doi.org\/10.1186\/s12974-023-02796-9","journal-title":"J Neuroinflammation"},{"key":"3787_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2020.04.002","volume":"93","author":"A-V Idland","year":"2020","unstructured":"Idland A-V, Sala-Llonch R, Watne LO, Br\u00e6khus A, Hansson O, Blennow K, et al. Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. Neurobiol Aging. 2020;93:1\u201315. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.04.002","journal-title":"Neurobiol Aging"},{"key":"3787_CR61","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/acn3.266","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Hertze J, Zetterberg H, Landqvist Wald\u00f6 M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2016;3:12\u201320. https:\/\/doi.org\/10.1002\/acn3.266","journal-title":"Ann Clin Transl Neurol"},{"key":"3787_CR62","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-023-01168-y","volume":"15","author":"SC Johnson","year":"2023","unstructured":"Johnson SC, Su\u00e1rez-Calvet M, Suridjan I, Minguill\u00f3n C, Gispert JD, Jonaitis E, et al. Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit. Alzheimer\u2019s Res Therapy. 2023;15:25. https:\/\/doi.org\/10.1186\/s13195-023-01168-y","journal-title":"Alzheimer\u2019s Res Therapy"},{"key":"3787_CR63","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3233\/jad-180855","volume":"67","author":"PE Khoonsari","year":"2019","unstructured":"Khoonsari PE, Shevchenko G, Herman S, Remnest\u00e5l J, Giedraitis V, Brundin R, et al. Improved differential diagnosis of Alzheimer\u2019s disease by integrating ELISA and mass spectrometry-based cerebrospinal fluid biomarkers. J Alzheimers Dis. 2019;67:639\u201351. https:\/\/doi.org\/10.3233\/jad-180855","journal-title":"J Alzheimers Dis"},{"key":"3787_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03611-5","volume":"24","author":"RM Lane","year":"2024","unstructured":"Lane RM, Darreh-Shori T, Junge C, Li D, Yang Q, Edwards AL, et al. Onset of Alzheimer disease in apolipoprotein \u025b4 carriers is earlier in butyrylcholinesterase K variant carriers. BMC Neurol. 2024;24:116. https:\/\/doi.org\/10.1186\/s12883-024-03611-5","journal-title":"BMC Neurol"},{"key":"3787_CR65","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/acn3.51671","volume":"9","author":"M Li","year":"2022","unstructured":"Li M, Ma Y-H, Fu Y, Liu J-Y, Hu H-Y, Zhao Y-L, et al. Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study. Ann Clin Transl Neurol. 2022;9:1752\u201363. https:\/\/doi.org\/10.1002\/acn3.51671","journal-title":"Ann Clin Transl Neurol"},{"key":"3787_CR66","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fnagi.2024.1339163","volume":"16","author":"Q-Y Li","year":"2024","unstructured":"Li Q-Y, Fu Y, Cui X-J, Wang Z-T, Tan L, ftAsDNI. Association of modified dementia risk score with cerebrospinal fluid biomarkers and cognition in adults without dementia. Front Aging Neurosci. 2024;16:2024. https:\/\/doi.org\/10.3389\/fnagi.2024.1339163","journal-title":"Front Aging Neurosci"},{"key":"3787_CR67","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3233\/jad-220598","volume":"90","author":"TR Li","year":"2022","unstructured":"Li TR, Lyu DY, Liu FQ. Cerebrospinal fluid sTREM2 in Alzheimer\u2019s disease is associated with both amyloid and tau pathologies but not with cognitive status. J Alzheimers Dis. 2022;90:1123\u201338. https:\/\/doi.org\/10.3233\/jad-220598","journal-title":"J Alzheimers Dis"},{"key":"3787_CR68","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3389\/fnagi.2019.00297","volume":"11","author":"C Liu","year":"2019","unstructured":"Liu C, Yu J. Genome-wide association studies for cerebrospinal fluid soluble TREM2 in Alzheimer\u2019s disease. Front Aging Neurosci. 2019;11:2019. https:\/\/doi.org\/10.3389\/fnagi.2019.00297","journal-title":"Front Aging Neurosci"},{"key":"3787_CR69","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3233\/jad-150897","volume":"50","author":"KE Melah","year":"2016","unstructured":"Melah KE, Lu SY, Hoscheidt SM, Alexander AL, Adluru N, Destiche DJ, et al. Cerebrospinal fluid markers of Alzheimer\u2019s disease pathology and microglial activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer\u2019s disease. J Alzheimers Dis. 2016;50:873\u201386. https:\/\/doi.org\/10.3233\/jad-150897","journal-title":"J Alzheimers Dis"},{"key":"3787_CR70","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1212\/wnl.0000000000012257","volume":"97","author":"EE Moore","year":"2021","unstructured":"Moore EE, Liu D, Li J, Schimmel SJ, Cambronero FE, Terry JG, et al. Association of aortic stiffness with biomarkers of neuroinflammation, synaptic dysfunction, and neurodegeneration. Neurology. 2021;97:e329\u2013e40. https:\/\/doi.org\/10.1212\/wnl.0000000000012257","journal-title":"Neurology"},{"key":"3787_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44173-8","volume":"9","author":"E Morenas-Rodr\u00edguez","year":"2019","unstructured":"Morenas-Rodr\u00edguez E, Alcolea D, Su\u00e1rez-Calvet M, Mu\u00f1oz-Llahuna L, Vilaplana E, Sala I, et al. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer\u2019s disease. Sci Rep. 2019;9:7803. https:\/\/doi.org\/10.1038\/s41598-019-44173-8","journal-title":"Sci Rep"},{"key":"3787_CR72","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3233\/JAD-170220","volume":"59","author":"P Muszy\u0144ski","year":"2017","unstructured":"Muszy\u0144ski P, Kulczy\u0144ska-Przybik A, Borawska R, Litman-Zawadzka A, S\u0142owik A, Klimkowicz-Mrowiec A, et al. The relationship between markers of inflammation and degeneration in the central nervous system and the blood-brain barrier impairment in Alzheimer\u2019s disease. J of Alzheimer\u2019s Dis. 2017;59:903\u201312. https:\/\/doi.org\/10.3233\/JAD-170220","journal-title":"J of Alzheimer\u2019s Dis"},{"key":"3787_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66211-w","volume":"14","author":"F Nabizadeh","year":"2024","unstructured":"Nabizadeh F, Seyedmirzaei H, Karami S. Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer\u2019s disease: a longitudinal study. Sci Rep. 2024;14:15318. https:\/\/doi.org\/10.1038\/s41598-024-66211-w","journal-title":"Sci Rep"},{"key":"3787_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1399-2","volume":"16","author":"K Nordengen","year":"2019","unstructured":"Nordengen K, Kirsebom B-E, Henjum K, Selnes P, G\u00edslad\u00f3ttir B, Wettergreen M, et al. Glial activation and inflammation along the Alzheimer\u2019s disease continuum. J Neuroinflammation. 2019;16:46. https:\/\/doi.org\/10.1186\/s12974-019-1399-2","journal-title":"J Neuroinflammation"},{"key":"3787_CR75","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/jad-2012-120787","volume":"33","author":"B Olsson","year":"2013","unstructured":"Olsson B, Hertze J, Lautner R, Zetterberg H, N\u00e4gga K, H\u00f6glund K, et al. Microglial markers are elevated in the prodromal phase of Alzheimer\u2019s disease and vascular dementia. J Alzheimers Dis. 2013;33:45\u201353. https:\/\/doi.org\/10.3233\/jad-2012-120787","journal-title":"J Alzheimers Dis"},{"key":"3787_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92101-6","volume":"11","author":"S-H Park","year":"2021","unstructured":"Park S-H, Lee E-H, Kim H-J, Jo S, Lee S, Seo SW, et al. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer\u2019s disease. Sci Rep. 2021;11:13050. https:\/\/doi.org\/10.1038\/s41598-021-92101-6","journal-title":"Sci Rep"},{"key":"3787_CR77","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","volume":"27","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27:1592\u20139. https:\/\/doi.org\/10.1038\/s41591-021-01456-w","journal-title":"Nat Med"},{"key":"3787_CR78","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/alz.13450","volume":"20","author":"W Pelkmans","year":"2024","unstructured":"Pelkmans W, Shekari M, Brugulat-Serrat A, S\u00e1nchez-Benavides G, Minguill\u00f3n C, Fauria K, et al. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer\u2019s disease progression. Alzheimers Dement. 2024;20:483\u201393. https:\/\/doi.org\/10.1002\/alz.13450","journal-title":"Alzheimers Dement"},{"key":"3787_CR79","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43587-022-00310-z","volume":"2","author":"JB Pereira","year":"2022","unstructured":"Pereira JB, Janelidze S, Strandberg O, Whelan CD, Zetterberg H, Blennow K, et al. Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer\u2019s disease pathology. Nat Aging. 2022;2:1138\u201344. https:\/\/doi.org\/10.1038\/s43587-022-00310-z","journal-title":"Nat Aging"},{"key":"3787_CR80","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","volume":"131","author":"L Piccio","year":"2016","unstructured":"Piccio L, Deming Y, Del-\u00c1guila JL, Ghezzi L, Holtzman DM, Fagan AM, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925\u201333. https:\/\/doi.org\/10.1007\/s00401-016-1533-5","journal-title":"Acta Neuropathol"},{"key":"3787_CR81","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3389\/fnagi.2021.676744","volume":"13","author":"JA Pillai","year":"2021","unstructured":"Pillai JA, Khrestian M, Bena J, Leverenz JB, Bekris LM. Temporal ordering of inflammatory analytes sTNFR2 and sTREM2 in relation to Alzheimer\u2019s disease biomarkers and clinical outcomes. Front Aging Neurosci. 2021;13:2021. https:\/\/doi.org\/10.3389\/fnagi.2021.676744","journal-title":"Front Aging Neurosci"},{"key":"3787_CR82","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/neurolint15030053","volume":"15","author":"E\u0160 Popova\u010dki","year":"2023","unstructured":"Popova\u010dki E\u0160, Babi\u0107 Leko M, Langer Horvat L, Brgi\u0107 K, Vogrinc \u017d, Boban M, et al. Soluble TREM2 concentrations in the cerebrospinal fluid correlate with the severity of neurofibrillary degeneration, cognitive impairment, and inflammasome activation in Alzheimer\u2019s disease. Neurol Int. 2023;15:842\u201356.","journal-title":"Neurol Int"},{"key":"3787_CR83","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-022-01051-2","volume":"14","author":"S Prins","year":"2022","unstructured":"Prins S, de Kam ML, Teunissen CE, Groeneveld GJ. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2022;14:106. https:\/\/doi.org\/10.1186\/s13195-022-01051-2","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"3787_CR84","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neurobiolaging.2018.10.022","volume":"74","author":"B-S Rauchmann","year":"2019","unstructured":"Rauchmann B-S, Schneider-Axmann T, Alexopoulos P, Perneczky R. CSF soluble TREM2 as a measure of immune response along the Alzheimer\u2019s disease continuum. Neurobiol Aging. 2019;74:182\u201390. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.10.022","journal-title":"Neurobiol Aging"},{"key":"3787_CR85","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000362164","volume":"4","author":"C Ros\u00e9n","year":"2014","unstructured":"Ros\u00e9n C, Andersson CH, Andreasson U, Molinuevo JL, Bjerke M, Rami L, et al. Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Dis Extra. 2014;4:297\u2013304. https:\/\/doi.org\/10.1159\/000362164","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"3787_CR86","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/jnc.14680","volume":"149","author":"J Schaeverbeke","year":"2019","unstructured":"Schaeverbeke J, Gille B, Adamczuk K, Vanderstichele H, Chassaing E, Bruffaerts R, et al. Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults. J Neurochem. 2019;149:139\u201357. https:\/\/doi.org\/10.1111\/jnc.14680","journal-title":"J Neurochem"},{"key":"3787_CR87","doi-asserted-by":"publisher","first-page":"10523","DOI":"10.3390\/ijms241310523","volume":"24","author":"I Schmidt-Morgenroth","year":"2023","unstructured":"Schmidt-Morgenroth I, Michaud P, Gasparini F, Avrameas A. Central and peripheral inflammation in mild cognitive impairment in the context of Alzheimer\u2019s disease. Int J Mol Sci. 2023;24:10523.","journal-title":"Int J Mol Sci"},{"key":"3787_CR88","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-024-01665-8","volume":"17","author":"Z Sheng","year":"2025","unstructured":"Sheng Z, Wang L, Chen M, Zhong F, Wu S, Liang S, et al. Cerebrospinal fluid \u03b22-microglobulin promotes the tau pathology through microglia\u2013astrocyte communication in Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2025;17:2. https:\/\/doi.org\/10.1186\/s13195-024-01665-8","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"3787_CR89","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","volume":"14","author":"CL Sutphen","year":"2018","unstructured":"Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, et al. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:869\u201379. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.012","journal-title":"Alzheimers Dement"},{"key":"3787_CR90","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fnagi.2022.876019","volume":"14","author":"UD Teitsdottir","year":"2022","unstructured":"Teitsdottir UD, Darreh-Shori T, Lund SH, Jonsdottir MK, Snaedal J, Petersen PH. Phenotypic displays of cholinergic enzymes associate with markers of inflammation, neurofibrillary tangles, and neurodegeneration in pre- and early symptomatic dementia subjects. Front Aging Neurosci. 2022;14:2022. https:\/\/doi.org\/10.3389\/fnagi.2022.876019","journal-title":"Front Aging Neurosci"},{"key":"3787_CR91","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13195-020-00657-8","volume":"12","author":"UD Teitsdottir","year":"2020","unstructured":"Teitsdottir UD, Jonsdottir MK, Lund SH, Darreh-Shori T, Snaedal J, Petersen PH. Association of glial and neuronal degeneration markers with Alzheimer\u2019s disease cerebrospinal fluid profile and cognitive functions. Alzheimer\u2019s Res Ther. 2020;12:92. https:\/\/doi.org\/10.1186\/s13195-020-00657-8","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"3787_CR92","doi-asserted-by":"publisher","first-page":"e1608","DOI":"10.1212\/wnl.0000000000011612","volume":"96","author":"S Toppala","year":"2021","unstructured":"Toppala S, Ekblad LL, Tuisku J, Helin S, Johansson JJ, Laine H, et al. Association of early \u03b2-Amyloid accumulation and neuroinflammation measured with [(11)C]PBR28 in elderly individuals without dementia. Neurology. 2021;96:e1608\u2013e19. https:\/\/doi.org\/10.1212\/wnl.0000000000011612","journal-title":"Neurology"},{"key":"3787_CR93","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/alz.12204","volume":"17","author":"C Van Hulle","year":"2021","unstructured":"Van Hulle C, Jonaitis EM, Betthauser TJ, Batrla R, Wild N, Kollmorgen G, et al. An examination of a novel multipanel of CSF biomarkers in the Alzheimer\u2019s disease clinical and pathological continuum. Alzheimer\u2019s Dement. 2021;17:431\u201345. https:\/\/doi.org\/10.1002\/alz.12204","journal-title":"Alzheimer\u2019s Dement"},{"key":"3787_CR94","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neurobiolaging.2020.07.009","volume":"96","author":"A Vergallo","year":"2020","unstructured":"Vergallo A, Lista S, Lemercier P, Chiesa PA, Zetterberg H, Blennow K, et al. Association of plasma YKL-40 with brain amyloid-\u03b2 levels, memory performance, and sex in subjective memory complainers. Neurobiol Aging. 2020;96:22\u201332. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.07.009","journal-title":"Neurobiol Aging"},{"key":"3787_CR95","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/s41380-024-02753-9","volume":"30","author":"C Vila-Castelar","year":"2025","unstructured":"Vila-Castelar C, Akinci M, Palpatzis E, Aguilar-Dominguez P, Operto G, Kollmorgen G, et al. Sex\/gender effects of glial reactivity on preclinical Alzheimer\u2019s disease pathology. Mol Psychiatry. 2025;30:1430\u20139. https:\/\/doi.org\/10.1038\/s41380-024-02753-9","journal-title":"Mol Psychiatry"},{"key":"3787_CR96","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1177\/13872877241291969","volume":"102","author":"L-Y Wang","year":"2024","unstructured":"Wang L-Y, Hu H, Sheng Z-H, Hu H-Y, Zhang Z-H, Tan L. Associations among healthy lifestyle characteristics, neuroinflammation, and cerebrospinal fluid core biomarkers of Alzheimer\u2019s disease in cognitively intact adults: The CABLE study. J Alzheimer\u2019s Dis. 2024;102:855\u201365. https:\/\/doi.org\/10.1177\/13872877241291969","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3787_CR97","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1002\/alz.13862","volume":"20","author":"N Warmenhoven","year":"2024","unstructured":"Warmenhoven N, S\u00e1nchez-Benavides G, Gonz\u00e1lez-Escalante A, Mil\u00e0-Alom\u00e0 M, Shekari M, L\u00f3pez-Martos D, et al. CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer\u2019s disease. Alzheimers Dement. 2024;20:5819\u201332. https:\/\/doi.org\/10.1002\/alz.13862","journal-title":"Alzheimers Dement"},{"key":"3787_CR98","doi-asserted-by":"publisher","first-page":"e0135458","DOI":"10.1371\/journal.pone.0135458","volume":"10","author":"M Wennstr\u00f6m","year":"2015","unstructured":"Wennstr\u00f6m M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, et al. The inflammatory marker YKL-40 Is elevated in cerebrospinal fluid from patients with alzheimer\u2019s but not Parkinson\u2019s disease or dementia with lewy bodies. PLoS One. 2015;10:e0135458. https:\/\/doi.org\/10.1371\/journal.pone.0135458","journal-title":"PLoS One"},{"key":"3787_CR99","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.neurobiolaging.2022.06.013","volume":"118","author":"RL Winfree","year":"2022","unstructured":"Winfree RL, Dumitrescu L, Blennow K, Zetterberg H, Gifford KA, Pechman KR, et al. Biological correlates of elevated soluble TREM2 in cerebrospinal fluid. Neurobiol Aging. 2022;118:88\u201398. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2022.06.013","journal-title":"Neurobiol Aging"},{"key":"3787_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105755","volume":"170","author":"Q Zeng","year":"2022","unstructured":"Zeng Q, Li K, Luo X, Wang S, Xu X, Jiaerken Y, et al. The association of enlarged perivascular space with microglia-related inflammation and Alzheimer\u2019s pathology in cognitively normal elderly. Neurobiol Dis. 2022;170:105755. https:\/\/doi.org\/10.1016\/j.nbd.2022.105755","journal-title":"Neurobiol Dis"},{"key":"3787_CR101","doi-asserted-by":"publisher","unstructured":"Zhao A, Jiao Y, Ye G, Kang W, Tan L, Li Y, et al. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer\u2019s disease. J Clin Invest. 2022;132. https:\/\/doi.org\/10.1172\/jci158708","DOI":"10.1172\/jci158708"},{"key":"3787_CR102","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1038\/npp.2014.164","volume":"39","author":"T Jiang","year":"2014","unstructured":"Jiang T, Tan L, Zhu X-C, Zhang Q-Q, Cao L, Tan M-S, et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer\u2019s disease. Neuropsychopharmacology. 2014;39:2949\u201362. https:\/\/doi.org\/10.1038\/npp.2014.164","journal-title":"Neuropsychopharmacology"},{"key":"3787_CR103","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nature06616","volume":"451","author":"M Meyer-Luehmann","year":"2008","unstructured":"Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer\u2019s disease. Nature. 2008;451:720\u20134. https:\/\/doi.org\/10.1038\/nature06616","journal-title":"Nature"},{"key":"3787_CR104","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med. 2019;11:e11170. https:\/\/doi.org\/10.15252\/emmm.201911170","journal-title":"EMBO Mol Med"},{"key":"3787_CR105","doi-asserted-by":"publisher","first-page":"369ra178","DOI":"10.1126\/scitranslmed.aag1767","volume":"8","author":"M Su\u00e1rez-Calvet","year":"2016","unstructured":"Su\u00e1rez-Calvet M, Araque Caballero M\u00c1, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8:369ra178\u2013369ra178. https:\/\/doi.org\/10.1126\/scitranslmed.aag1767","journal-title":"Sci Transl Med"},{"key":"3787_CR106","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.neuron.2021.02.010","volume":"109","author":"S-H Lee","year":"2021","unstructured":"Lee S-H, Meilandt WJ, Xie L, Gandham VD, Ngu H, Barck KH, et al. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by \u03b2-amyloid pathology. Neuron. 2021;109:1283\u2013301.e6. https:\/\/doi.org\/10.1016\/j.neuron.2021.02.010","journal-title":"Neuron"},{"key":"3787_CR107","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41593-019-0433-0","volume":"22","author":"CEG Leyns","year":"2019","unstructured":"Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, et al. TREM2 function impedes tau seeding in neuritic plaques. Nat Neurosci. 2019;22:1217\u201322. https:\/\/doi.org\/10.1038\/s41593-019-0433-0","journal-title":"Nat Neurosci"},{"key":"3787_CR108","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jalz.2014.12.009","volume":"11","author":"CM Lill","year":"2015","unstructured":"Lill CM, Rengmark A, Pihlstr\u00f8m L, Fogh I, Shatunov A, Sleiman PM, et al. The role of TREM2 R47H as a risk factor for Alzheimer\u2019s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson\u2019s disease. Alzheimer\u2019s Dement. 2015;11:1407\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2014.12.009","journal-title":"Alzheimer\u2019s Dement"},{"key":"3787_CR109","doi-asserted-by":"publisher","unstructured":"Ewers M, Franzmeier N, Su\u00e1rez-Calvet M, Morenas-Rodriguez E, Caballero MAA, Kleinberger G, et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer\u2019s disease. Sci Transl Med. 2019;11. https:\/\/doi.org\/10.1126\/scitranslmed.aav6221","DOI":"10.1126\/scitranslmed.aav6221"},{"key":"3787_CR110","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(22)00027-8","volume":"21","author":"E Morenas-Rodr\u00edguez","year":"2022","unstructured":"Morenas-Rodr\u00edguez E, Li Y, Nuscher B, Franzmeier N, Xiong C, Su\u00e1rez-Calvet M, et al. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer\u2019s disease: a longitudinal observational study. Lancet Neurol. 2022;21:329\u201341. https:\/\/doi.org\/10.1016\/S1474-4422(22)00027-8","journal-title":"Lancet Neurol"},{"key":"3787_CR111","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13024-020-00407-2","volume":"15","author":"N Franzmeier","year":"2020","unstructured":"Franzmeier N, Su\u00e1rez-Calvet M, Frontzkowski L, Moore A, Hohman TJ, Morenas-Rodriguez E, et al. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Mol Neurodegener. 2020;15:57. https:\/\/doi.org\/10.1186\/s13024-020-00407-2","journal-title":"Mol Neurodegener"},{"key":"3787_CR112","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12128","volume":"12","author":"TH Edwin","year":"2020","unstructured":"Edwin TH, Henjum K, Nilsson LNG, Watne LO, Persson K, Eldholm RS, et al. A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer\u2019s disease. Alzheimer\u2019s Dement: Diagn Assess Dis Monit. 2020;12:e12128. https:\/\/doi.org\/10.1002\/dad2.12128","journal-title":"Alzheimer\u2019s Dement: Diagn Assess Dis Monit"},{"key":"3787_CR113","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","volume":"7","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer\u2019s disease in a memory clinic cohort. Alzheimers Res Ther. 2015;7:59. https:\/\/doi.org\/10.1186\/s13195-015-0142-1","journal-title":"Alzheimers Res Ther"},{"key":"3787_CR114","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1212\/wnl.0000000000006082","volume":"91","author":"S Janelidze","year":"2018","unstructured":"Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91:e867\u2013e77. https:\/\/doi.org\/10.1212\/wnl.0000000000006082","journal-title":"Neurology"},{"key":"3787_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2025.1630022","volume":"17","author":"YY Wang","year":"2025","unstructured":"Wang YY, Zhang M, Chen SJ, Miao W, Wang ZX, Zhou YJ, et al. Neuroinflammation-mediated YKL-40 correlates with tau pathology and predicts longitudinal cognitive impairment and brain atrophy in Alzheimer\u2019s disease, with hypertensive dependency. Front Aging Neurosci. 2025;17:1630022. https:\/\/doi.org\/10.3389\/fnagi.2025.1630022","journal-title":"Front Aging Neurosci"},{"key":"3787_CR116","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2023.12.001","volume":"57","author":"A Millet","year":"2024","unstructured":"Millet A, Ledo JH, Tavazoie SF. An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer\u2019s brains. Immunity. 2024;57:153\u201370.e6. https:\/\/doi.org\/10.1016\/j.immuni.2023.12.001","journal-title":"Immunity"},{"key":"3787_CR117","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/bpa.12456","volume":"27","author":"DS Davies","year":"2017","unstructured":"Davies DS, Ma J, Jegathees T, Goldsbury C. Microglia show altered morphology and reduced arborization in human brain during aging and Alzheimer\u2019s disease. Brain Pathol. 2017;27:795\u2013808. https:\/\/doi.org\/10.1111\/bpa.12456","journal-title":"Brain Pathol"},{"key":"3787_CR118","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","volume":"101","author":"J Wiltfang","year":"2007","unstructured":"Wiltfang J, Esselmann H, Bibl M, H\u00fcll M, Hampel H, Kessler H, et al. Amyloid \u03b2 peptide ratio 42\/40 but not A\u03b242 correlates with phospho-Tau in patients with low- and high-CSF A\u03b240 load. J Neurochem. 2007;101:1053\u20139. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04404.x","journal-title":"J Neurochem"},{"key":"3787_CR119","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s44321-024-00190-3","volume":"17","author":"D Biel","year":"2025","unstructured":"Biel D, Su\u00e1rez-Calvet M, Dewenter A, Steward A, Roemer SN, Dehsarvi A, et al. Female sex is linked to a stronger association between sTREM2 and CSF p-tau in Alzheimer\u2019s disease. EMBO Mol Med. 2025;17:235\u201348. https:\/\/doi.org\/10.1038\/s44321-024-00190-3","journal-title":"EMBO Mol Med"},{"key":"3787_CR120","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1212\/01.wnl.0000260269.93245.d2","volume":"68","author":"CG Lyketsos","year":"2007","unstructured":"Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800\u20138. https:\/\/doi.org\/10.1212\/01.wnl.0000260269.93245.d2","journal-title":"Neurology"},{"key":"3787_CR121","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.clinbiochem.2019.04.001","volume":"72","author":"T Ozben","year":"2019","unstructured":"Ozben T, Ozben S. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer\u2019s disease. Clin Biochem. 2019;72:87\u20139. https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.04.001","journal-title":"Clin Biochem"},{"key":"3787_CR122","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41591-025-03574-1","volume":"31","author":"L van Olst","year":"2025","unstructured":"van Olst L, Simonton B, Edwards AJ, Forsyth AV, Boles J, Jamshidi P, et al. Microglial mechanisms drive amyloid-\u03b2 clearance in immunized patients with Alzheimer\u2019s disease. Nat Med. 2025;31:1604\u201316. https:\/\/doi.org\/10.1038\/s41591-025-03574-1","journal-title":"Nat Med"},{"key":"3787_CR123","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/wnl.0000000000002923","volume":"87","author":"CR Jack Jr.","year":"2016","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539\u201347. https:\/\/doi.org\/10.1212\/wnl.0000000000002923","journal-title":"Neurology"},{"key":"3787_CR124","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.jalz.2019.07.009","volume":"15","author":"MM Mielke","year":"2019","unstructured":"Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Vemuri P, et al. Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. Alzheimers Dement. 2019;15:1437\u201347. https:\/\/doi.org\/10.1016\/j.jalz.2019.07.009","journal-title":"Alzheimers Dement"},{"key":"3787_CR125","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1038\/s41380-025-03021-0","volume":"30","author":"D Mengel","year":"2025","unstructured":"Mengel D, Soter E, Ott JM, Wacker M, Leyva A, Peters O, et al. Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer\u00b4s disease. Mol Psychiatry. 2025;30:3150\u20139. https:\/\/doi.org\/10.1038\/s41380-025-03021-0","journal-title":"Mol Psychiatry"},{"key":"3787_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03432-4","volume":"22","author":"BM Bettcher","year":"2025","unstructured":"Bettcher BM, de Oliveira FF, Willette AA, Michalowska MM, Machado LS, Rajbanshi B, et al. Analysis and interpretation of inflammatory fluid markers in Alzheimer\u2019s disease: a roadmap for standardization. J Neuroinflammation. 2025;22:105. https:\/\/doi.org\/10.1186\/s12974-025-03432-4","journal-title":"J Neuroinflammation"},{"key":"3787_CR127","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/alz.12415","volume":"18","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Aakre JA, Algeciras-Schimnich A, Proctor NK, Machulda MM, Eichenlaub U, et al. Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimers Dement. 2022;18:602\u201311. https:\/\/doi.org\/10.1002\/alz.12415","journal-title":"Alzheimers Dement"},{"key":"3787_CR128","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0","journal-title":"Lancet Neurol"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03787-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:57:02Z","timestamp":1787662622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03787-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":128,"alternative-id":["3787"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03787-x","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article. Author disclosures are available in the\u00a0\n                      \n                      .","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}